EngeneIC is a biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of chemotherapeutics and functional nucleic acids in cancer. The EDV™ is a first-in-class Cyto-Immunotherapy platform.
| Website | http://engeneic.com/ |
| Revenue | $5.2 million |
| Employees | 14 (14 on RocketReach) |
| Founded | 2001 |
| Competitors | Johnson & Johnson, Roche, Merck & Co., Inc., Pfizer, Sanofi, GSK, AstraZeneca, Bristol Myers Squibb, Genentech, Amgen +43 more (view full list) |
Looking for a particular EnGeneIC employee's phone or email?
The EnGeneIC annual revenue was $5.2 million in 2026.
Nancy Mugridge is the VP, Alliances of EnGeneIC.
14 people are employed at EnGeneIC.